Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy
Product Stage
Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker
Product Stage
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
Product Stage
Polyrizon Regains Compliance with Nasdaq Listing Requirements
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
Product Stage
Polyrizon Retains Nasdaq Listing Following Hearings Panel
PIPE/PO
Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics
Product Stage
Polyrizon Announces Receipt of Nasdaq Delisting Notice
Public Trading
Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform
Product Stage
Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment
Product Stage
Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model
Product StageFDA approved/pending approval
Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements
Polyrizon Engages Leading Branding Firm for Strategic Brand Development
PartnersProduct Stage
Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement
Investment
Polyrizon Ltd. Announces $17.0 Million Private Placement
Investment
Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting
Product Stage
Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment
Product StagePartners
Psychedelic: atai Life Sciences, NRx report quarterly results
InvestmentProduct Stage